Cita APA

Wang, W., Jiang, X., Zhang, Y., Song, Y., & Song, Z. (2019). Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients. J Thorac Dis.

Chicago Style Citation

Wang, Wenxian, Xiaowen Jiang, Yiping Zhang, Yong Song, i Zhengbo Song. "Intracavitary Chemotherapy With Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) Is Not Superior to TKI Monotherapy in Controlling Malignant Pleural Effusion Recurrence in EGFR-mutated Lung Cancer Patients." J Thorac Dis 2019.

Cita MLA

Wang, Wenxian, et al. "Intracavitary Chemotherapy With Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI) Is Not Superior to TKI Monotherapy in Controlling Malignant Pleural Effusion Recurrence in EGFR-mutated Lung Cancer Patients." J Thorac Dis 2019.